3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
6
Neoplasms
5
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Vomiting
1
Stomatitis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nausea
1
NSCLC
1
Mucositis
1
Mastocytosis, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Interventions
pembrolizumab
45
Paclitaxel
8
Cisplatin
8
Carboplatin
8
lenvatinib
7
Pemetrexed
5
Gemcitabine
4
camrelizumab
3
Docetaxel
3
Capecitabine
3
epacadostat
2
avelumab
2
Fluorouracil
2
Cetuximab
2
Acetaminophen
2
vicriviroc
1
sinoporphyrin sodium
1
penpulimab
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
balstilimab
1
apatinib
1
Temozolomide
1
Tadalafil
1
Standard of Care
1
Serotonin 5-HT3 Receptor Antagonists
1
Radiotherapy
1
Radiosurgery
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Diphenhydramine
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts